| Outcome Measures: |
Primary: Participant Preference Between 2 Injection Devices Based on Global Preference Item, Preference of injection device was assessed by questionnaire which asks, "Overall, which device do you prefer?" The Prescott test will be run to examine if a statistically significant difference in preference between the devices exits, while controlling for order effects and taking into account the neutral responses., Day 1 | Secondary: Participant Preference Between 2 Injection Devices Based on Ease of Use, Participants responded to the Diabetes Injection Device - Preference Questionnaire (DID-PQ), Item 9 (ease of use) to compare the dulaglutide and semaglutide devices with regard to ease. Response options of "strongly prefer" and "prefer" were combined for each device, resulting in 3 categories: prefer dulaglutide, prefer semaglutide, and no preference. The Prescott test will be run to examine if a statistically significant difference in preference between the devices exists while, controlling for order effects., Day 1
|
| Locations: |
Valley Research, Fresno, California, 93720, United States|Long Beach Center for Clinical Research, Long Beach, California, 90807, United States|Palm Harbor Medical Associates, Palm Harbor, Florida, 34684, United States|Georgia Clinical Research, Snellville, Georgia, 30078, United States|Cedar-Crosse Research Center, Chicago, Illinois, 60607, United States|L-Marc Research Center, Louisville, Kentucky, 40213, United States|Evidera, Bethesda, Maryland, 20814, United States|Carolina Research Center, Inc., Shelby, North Carolina, 28150, United States|Lillestol Research LLC, Fargo, North Dakota, 58104, United States|BRCR Medical Center, Inc., Camp Hill, Pennsylvania, 17011, United States|Juno Research, Houston, Texas, 77040, United States|Juno Research, LLC, Houston, Texas, 77054, United States|PI-Coor Clinical Research, LLC, Annandale, Virginia, 22003, United States|Manassas Clinical Research Center, Manassas, Virginia, 20110, United States
|
